PTHS|Pelthos Therapeutics Ord Shs|Price:26.720|Chg%:-1.23

More Details of Company

Pelthos Therapeutics Ord Shs Info



Ticker Symbol- -

Company name- -

IPO date- -

CEO- -

Number of employees- -

Security type- -

Fiscal year-end- -

Address- -

City- -

Stock exchange- -

Country- -

Postal code- -

Phone- -

Website- -

Ticker Symbol- -

IPO date- -

CEO- -

Company Executives of Pelthos Therapeutics Ord Shs



Name

Name/Position

Position

Shareholding

Change

Mr. Ezra M. Friedberg

Independent Director

64.08K

-0.87%

Mr. Sai Rangarao

Chief Commercial Officer

30.52K

--

Dr. Richard Malamut

Independent Director

10.52K

-5.61%

Mr. Richard Baxter

Independent Director

3.19K

-499.94%

Mr. Francis P. (Frank) Knuettel, II

Chief Financial Officer, Treasurer, Company Secretary

--

Mr. Todd C. Davis

Independent Director

--

Mr. Peter Greenleaf

Chairman of the Board

--

Mr. Matthew Pauls

Independent Director

--

Mr. Scott Plesha

President, Chief Executive Officer, Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. Ezra M. Friedberg

Independent Director

64.08K

-0.87%

Mr. Sai Rangarao

Chief Commercial Officer

30.52K

--

Dr. Richard Malamut

Independent Director

10.52K

-5.61%

Mr. Richard Baxter

Independent Director

3.19K

-499.94%

Mr. Francis P. (Frank) Knuettel, II

Chief Financial Officer, Treasurer, Company Secretary

--

Mr. Todd C. Davis

Independent Director

--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.

Relevant data have not been disclosed by the company yet.

By Business

By Region

Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Sun, May 10

Shareholders

Shareholder Types

Shareholders

Proportion

Ligand Pharmaceuticals Inc

44.70%

Murchinson Ltd.

8.34%

Ikarian Capital LLC

7.62%

3I Management LLC

6.36%

Vanguard Capital Management, LLC

2.77%

Other

30.19%

Shareholders

Proportion

Ligand Pharmaceuticals Inc

44.70%

Murchinson Ltd.

8.34%

Ikarian Capital LLC

7.62%

3I Management LLC

6.36%

Vanguard Capital Management, LLC

2.77%

Other

30.19%

Shareholder Types

Shareholders

Proportion

Corporation

48.34%

Investment Advisor/Hedge Fund

17.52%

Hedge Fund

11.77%

Individual Investor

7.78%

Investment Advisor

4.19%

Private Equity

0.24%

Other

10.15%

Institutional Shareholding



Updated: Wed, Apr 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2026Q4

20

762.76K

10.36%

--

2026Q1

30

1.21M

35.96%

+404.95K

2025Q4

23

771.24K

24.99%

+360.35K

2025Q3

23

762.76K

24.89%

+686.23K

2025Q2

15

44.89K

7.45%

-74.71K

2025Q1

14

89.69K

14.94%

-16.15K

2024Q4

11

77.19K

12.98%

+14.42K

2024Q3

10

38.99K

6.70%

-15.38K

2024Q2

7

54.38K

9.43%

+29.19K

2024Q1

2

57.07K

9.90%

+57.07K

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Ligand Pharmaceuticals Inc

1.50M

44.7%

--

Nov 24, 2025

Murchinson Ltd.

289.48K

8.63%

+9.48K

+3.39%

Dec 31, 2025

Ikarian Capital LLC

255.76K

7.62%

+193.31K

+309.53%

Dec 31, 2025

3I Management LLC

213.51K

6.36%

-86.49K

-28.83%

Dec 31, 2025

Balmoral Financial Group LLC

92.07K

2.74%

--

Nov 24, 2025

Boothbay Fund Management, LLC

80.68K

2.4%

+59.44K

+279.76%

Dec 31, 2025

J. Goldman & Co., L.P.

78.01K

2.32%

+78.01K

--

Dec 31, 2025

Related ETFs



Name

Proportion

No Data

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

Jun 27, 2025

Merger

10→1

Date

Ex-dividend Date

Type

Ratio

Jun 27, 2025

Merger

10→1